The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hippel-Lindau Disease

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hippel-Lindau Disease


Psychiatry related information on Hippel-Lindau Disease


High impact information on Hippel-Lindau Disease


Chemical compound and disease context of Hippel-Lindau Disease


Biological context of Hippel-Lindau Disease


Anatomical context of Hippel-Lindau Disease


Gene context of Hippel-Lindau Disease


Analytical, diagnostic and therapeutic context of Hippel-Lindau Disease


  1. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Gnarra, J.R., Zhou, S., Merrill, M.J., Wagner, J.R., Krumm, A., Papavassiliou, E., Oldfield, E.H., Klausner, R.D., Linehan, W.M. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  2. Hereditary tumor syndromes of the nervous system: overview and rare syndromes. Louis, D.N., von Deimling, A. Brain Pathol. (1995) [Pubmed]
  3. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. Zhou, M.I., Wang, H., Ross, J.J., Kuzmin, I., Xu, C., Cohen, H.T. J. Biol. Chem. (2002) [Pubmed]
  4. Software and database for the analysis of mutations in the VHL gene. Béroud, C., Joly, D., Gallou, C., Staroz, F., Orfanelli, M.T., Junien, C. Nucleic Acids Res. (1998) [Pubmed]
  5. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Olschwang, S., Richard, S., Boisson, C., Giraud, S., Laurent-Puig, P., Resche, F., Thomas, G. Hum. Mutat. (1998) [Pubmed]
  6. Genetic abnormalities of the endothelium. Butany, J.W., Verma, S., Leask, R.L., Mohsen, B., Asa, S.L. Microsc. Res. Tech. (2003) [Pubmed]
  7. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. Eisenhofer, G., Lenders, J.W., Linehan, W.M., Walther, M.M., Goldstein, D.S., Keiser, H.R. N. Engl. J. Med. (1999) [Pubmed]
  8. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Schmidt, L., Duh, F.M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S.W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U.R., Feltis, J.T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C.J., Walther, M.M., Tsui, L.C., Geil, L., Orcutt, M.L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M.D., Moch, H., Storkel, S., Lerman, M.I., Linehan, W.M., Zbar, B. Nat. Genet. (1997) [Pubmed]
  9. Natural killer (NK) cell lytic dysfunction and putative NK cell receptor expression abnormality in members of a family with chromosome 3p-linked von Hippel-Lindau disease. Ortaldo, J.R., Glenn, G.M., Young, H.A., Frey, J.L. J. Natl. Cancer Inst. (1992) [Pubmed]
  10. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Sgambati, M.T., Stolle, C., Choyke, P.L., Walther, M.M., Zbar, B., Linehan, W.M., Glenn, G.M. Am. J. Hum. Genet. (2000) [Pubmed]
  11. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Pollard, P.J., Brière, J.J., Alam, N.A., Barwell, J., Barclay, E., Wortham, N.C., Hunt, T., Mitchell, M., Olpin, S., Moat, S.J., Hargreaves, I.P., Heales, S.J., Chung, Y.L., Griffiths, J.R., Dalgleish, A., McGrath, J.A., Gleeson, M.J., Hodgson, S.V., Poulsom, R., Rustin, P., Tomlinson, I.P. Hum. Mol. Genet. (2005) [Pubmed]
  12. Central nervous system involvement in Von Hippel-Lindau disease. Filling-Katz, M.R., Choyke, P.L., Oldfield, E., Charnas, L., Patronas, N.J., Glenn, G.M., Gorin, M.B., Morgan, J.K., Linehan, W.M., Seizinger, B.R. Neurology (1991) [Pubmed]
  13. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. Vogel, T.W., Brouwers, F.M., Lubensky, I.A., Vortmeyer, A.O., Weil, R.J., Walther, M.M., Oldfield, E.H., Linehan, W.M., Pacak, K., Zhuang, Z. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  14. Long-term followup after nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. Novick, A.C., Streem, S.B. J. Urol. (1992) [Pubmed]
  15. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Aiello, L.P., George, D.J., Cahill, M.T., Wong, J.S., Cavallerano, J., Hannah, A.L., Kaelin, W.G. Ophthalmology (2002) [Pubmed]
  16. Epididymal cysts in children: natural history. Homayoon, K., Suhre, C.D., Steinhardt, G.F. J. Urol. (2004) [Pubmed]
  17. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Duan, D.R., Humphrey, J.S., Chen, D.Y., Weng, Y., Sukegawa, J., Lee, S., Gnarra, J.R., Linehan, W.M., Klausner, R.D. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  18. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka, M., da Silva, N.F., Clifford, S.C., Morris, M.R., Wiesener, M.S., Eckardt, K.U., Houlston, R.S., Richards, F.M., Latif, F., Maher, E.R. Cancer Res. (2002) [Pubmed]
  19. VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Vortmeyer, A.O., Choo, D., Pack, S., Oldfield, E., Zhuang, Z. Neurology (2000) [Pubmed]
  20. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. Chen, F., Slife, L., Kishida, T., Mulvihill, J., Tisherman, S.E., Zbar, B. J. Med. Genet. (1996) [Pubmed]
  21. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Crossey, P.A., Foster, K., Richards, F.M., Phipps, M.E., Latif, F., Tory, K., Jones, M.H., Bentley, E., Kumar, R., Lerman, M.I. Hum. Genet. (1994) [Pubmed]
  22. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. Manski, T.J., Heffner, D.K., Glenn, G.M., Patronas, N.J., Pikus, A.T., Katz, D., Lebovics, R., Sledjeski, K., Choyke, P.L., Zbar, B., Linehan, W.M., Oldfield, E.H. JAMA (1997) [Pubmed]
  23. Interferon alpha-2a therapy in 18 hemangioblastomas. Niemelä, M., Mäenpää, H., Salven, P., Summanen, P., Poussa, K., Laatikainen, L., Jääskeläinen, J., Joensuu, H. Clin. Cancer Res. (2001) [Pubmed]
  24. Craniospinal magnetic resonance imaging enhanced with Gd-DTPA in von Hippel-Lindau disease. Hardjasudarma, M., Fowler, M. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. (1991) [Pubmed]
  25. Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma. Satake, N., Urakami, S., Hirayama, Y., Izumi, K., Hino, O. Int. J. Cancer (1998) [Pubmed]
  26. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Los, M., Aarsman, C.J., Terpstra, L., Wittebol-Post, D., Lips, C.J., Blijham, G.H., Voest, E.E. Ann. Oncol. (1997) [Pubmed]
  27. Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease. Lamberts, S.W., Hofland, L.J., Lely, A.J., de Herder, W.W. J. Intern. Med. (1998) [Pubmed]
  28. History of the tuberous sclerosis complex. Gómez, M.R. Brain Dev. (1995) [Pubmed]
  29. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity. Panchenko, M.V., Zhou, M.I., Cohen, H.T. J. Biol. Chem. (2004) [Pubmed]
  30. Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Goldfarb, D.A. J. Intern. Med. (1998) [Pubmed]
  31. Cytogenetic and fluorescence in situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome (VHL). Decker, H.J., Klauck, S.M., Lawrence, J.B., McNeil, J., Smith, D., Gemmill, R.M., Sandberg, A.A., Neumann, H.H., Simon, B., Green, J. Cancer Genet. Cytogenet. (1994) [Pubmed]
WikiGenes - Universities